New Paradigms in Cancer Therapeutics

癌症治疗的新范式

• 批准号: 7804731
• 负责人: ANDREW D ROBERTSON
• 金额: $ 2万
• 依托单位: KEYSTONE SYMPOSIA
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-09 至 2011-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7804731
• 关键词: Academia; Address; Affect; Appearance; Biochemical Pathway; British Columbia; Canada; Cancer Etiology; Clinic; Collaborations; Combined Modality Therapy; Communities; Development; Epigenetic Process; Erinaceidae; Event; Gene Expression Profile; Gene Fusion; Genes; Genome; Goals; Individual; Industry; Institutes; Malignant Neoplasms; Medicine; Metabolic Pathway; Modality; Molecular; Molecular Profiling; Monitor; Mutation; Pathway interactions; Patients; Physiological; Process; Proteome; RNA Interference; Recurrence; Regimen; Research Personnel; Resistance; Role; Signal Pathway; Small Interfering RNA; Structure of molecular layer of cerebellar cortex; Technology; Therapeutic; Therapeutic Intervention; anticancer research; base; cancer therapy; improved; inhibitor/antagonist; innovation; meetings; member; molecular marker; novel; novel therapeutic intervention; research and development; resistance mechanism; stem cell niche; symposium; therapeutic target; tumor; tumor progression

DESCRIPTION (provided by applicant): This proposal is to request support for a Keystone Symposia meeting entitled New Paradigms in Cancer Therapeutics, organized by Arul M. Chinnaiyan and William R. Sellers, which will be held in British Columbia, Canada from March 23 - 28, 2010. The advent of genome-scale profiling technologies has opened up the possibility of comprehensively monitoring multiple layers of molecular aberrations in cancer. Alterations in the epigenome, genome, transcriptome, proteome and metabolome have all been observed in tumor development. A number of key molecular pathways have been found to be altered during cancer progression. Pivotal questions in the field include: Can these novel pathways alone or in combination be effectively targeted in cancer? Can we identify molecular signatures that will facilitate personalized medicine? What are the innovative therapeutic modalities that can be employed to target these pathways? The goal of this meeting is to tackle promising new targets for cancer therapy. These include targets such as recurrent gene fusions, epigenetic pathways, and metabolic networks. We will also explore the use of molecular marker panels to select patients for treatment. A number of approaches to therapeutic targeting will be discussed including novel biologics and RNA interference. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Integration of Developmental Signaling Pathways which will share a keynote address and a plenary session with this meeting.

描述(由申请人提供)：本提案旨在请求支持将于2010年3月23-28日在加拿大不列颠哥伦比亚省举办的题为癌症治疗新范例的Keystone研讨会。基因组规模图谱技术的出现为全面监测癌症中多层分子畸变提供了可能性。在肿瘤的发展过程中，表观基因组、基因组、转录组、蛋白质组和代谢组的改变都已被观察到。已发现许多关键的分子通路在癌症进展过程中发生了改变。该领域的关键问题包括：这些新途径能否单独或结合在一起有效地针对癌症？我们能识别出促进个性化医疗的分子签名吗？可以采用哪些创新的治疗方式来针对这些途径？ 这次会议的目标是解决癌症治疗的有希望的新目标。这些靶点包括重复的基因融合、表观遗传途径和代谢网络。我们还将探索使用分子标记面板来选择患者进行治疗。将讨论一些治疗靶向的方法，包括新型生物制剂和RNA干扰。同时举行的发展信号途径整合会议将大大增加跨学科互动的机会，该会议将与本次会议举行主旨演讲和全体会议。